Lab reports look definitive—bold numbers, colored flags, a "normal" range. In men's health, those numbers are only one input. Symptoms, timing, assay method, binding proteins, pituitary hormones, and competing conditions (sleep apnea, depression, obesity, medications) all shape what a result means for you.
This article is for education. It is not medical advice, diagnosis, or a treatment plan. Decisions about testosterone therapy (TRT) or related options belong with a licensed clinician who knows your history.
What it is
A typical men's hormone panel may include:
- Total testosterone — bound plus unbound hormone in serum
- Free testosterone (measured or calculated) — the unbound fraction more available to tissues
- SHBG (sex hormone-binding globulin) — a liver-made binding protein that strongly influences free T
- LH and FSH — pituitary signals that help separate primary (testicular) from secondary (pituitary/hypothalamic) patterns
- Often also: estradiol, CBC/hematocrit, PSA (when age- and risk-appropriate), and metabolic labs (glucose/A1C, lipids) — see 5 lab markers every man over 30 should know
MedlinePlus notes that testosterone testing is often done with a morning blood sample and that a low result may need confirmation with a second test—because levels vary and context matters.
How it works
Testosterone follows a diurnal rhythm; many guidelines emphasize morning draws. The Endocrine Society's 2018 clinical practice guideline recommends diagnosing hypogonadism only when symptoms/signs consistent with testosterone deficiency are present and serum testosterone is unequivocally and consistently low, preferably using accurate assays and repeating a fasting morning total testosterone measurement.
SHBG and free T. Much circulating testosterone is bound to SHBG and albumin. When SHBG is high, free T can be low even if total T looks "okay." When SHBG is low (common with obesity/insulin resistance), free T can look higher relative to total. Assays and calculation formulas differ; comparing serial results from the same lab and method is usually more useful than chasing an internet "optimal" chart.
LH/FSH. Measuring LH and FSH helps clinicians distinguish primary from secondary hypogonadism and decide what further evaluation (if any) is needed. Low or inappropriately normal gonadotropins with low T suggest a secondary pattern; high gonadotropins with low T suggest a primary (testicular) pattern.
What evidence shows
| Topic | Status | Notes |
|---|---|---|
| Diagnose hypogonadism only with symptoms + consistently low T | Established (guideline) | Endocrine Society 2018 |
| Prefer morning fasting total T; confirm with a second draw | Established (guideline) | Same guideline; MedlinePlus patient education aligns on morning/confirm |
| Use accurate assays; consider free T when total is borderline or SHBG is altered | Established (guideline) | Equilibrium dialysis preferred for free T when available; calculated free T is widely used |
| Routine population screening for hypogonadism | Not recommended | Endocrine Society recommends against routine screening of asymptomatic men |
| A single mid-range total T "proves" you feel fine | Unproven / not how labs work | Symptoms are multifactorial; ranges are statistical |
| Social-media "optimal" free T targets as clinical standards | Unproven | Not Endocrine Society standards |
Limitations: Reference ranges differ by assay (immunoassay vs LC-MS/MS) and lab population. Acute illness, shift work, poor sleep, opioids, glucocorticoids, and some supplements (e.g., high-dose biotin interfering with some immunoassays) can distort results. FDA labeling for testosterone products still frames therapy around conditions associated with deficiency or absence of endogenous testosterone, with product-specific limitations—labels are not a DIY lab decoder.
Risks (of misreading labs—or of treatment decisions based only on labs)
Misinterpreting a single afternoon draw, a non-confirmed low, or a forum screenshot can lead to:
- Unnecessary anxiety or unnecessary treatment pressure
- Missing reversible causes (sleep apnea, depression, thyroid disease, alcohol use, obesity)
- Starting exogenous testosterone without understanding fertility suppression, hematocrit rise, or monitoring needs
Exogenous testosterone can raise hematocrit; product labels and guidelines emphasize monitoring. PSA interpretation is age- and risk-dependent and is not a cancer diagnosis by itself (MedlinePlus). Therapy decisions require shared decision-making about benefits, uncertainties, and contraindications listed in guidelines (e.g., near-term fertility plans, certain prostate findings, elevated hematocrit, untreated severe OSA, recent major CV events, thrombophilia—per Endocrine Society).
Who should discuss with a clinician
Consider a clinician conversation if you have:
- Persistent symptoms suggestive of androgen deficiency plus low morning testosterone on repeat testing
- Borderline totals with conditions that alter SHBG (obesity, aging, thyroid disease, liver disease)
- Plans for near-term fertility (exogenous T typically suppresses spermatogenesis)
- Rising hematocrit, urinary symptoms, breast/prostate concerns, or cardiovascular history before any hormone therapy
- Interest in telehealth evaluation—labs still need clinical interpretation; emergencies are not telehealth (call 911)
Bottom Line
Total testosterone is a headline, not a full story. Free T/SHBG, LH/FSH, timing, assay quality, and symptoms together matter more than any one number. Guidelines require consistent low levels and clinical context—not a single "optimize me" screenshot.
So what?
If you already have a panel PDF, bring the full report (method, time of day, reference ranges) to a licensed clinician rather than self-dosing from the internet. If you have not been tested, ask whether morning, fasting, confirmatory testing fits your situation.
To learn how Scoreboard Health approaches evaluation and monitoring with licensed providers—not to order medication from a blog—see How it works or Treatments.
Related reading
Disclaimer: Educational content only. Not medical advice. Compounded medications, when offered through a clinic pathway, are not FDA-approved; FDA-approved products have product-specific labels. Always discuss personal risks and alternatives with a licensed clinician.
Medically reviewed by: Ana Argote, BSN, R.N.
Sources
- Bhasin S, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018. PubMed · Society summary
- MedlinePlus. Testosterone Levels Test. medlineplus.gov
- MedlinePlus. Hematocrit Test. medlineplus.gov
- MedlinePlus. Prostate-Specific Antigen (PSA) Test. medlineplus.gov
- U.S. FDA. FDA issues class-wide labeling changes for testosterone products (Feb 28, 2025). fda.gov
- Lincoff AM, et al. Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE). N Engl J Med. 2023. nejm.org
Learn how Scoreboard Health structures men's evaluation pathways: How it works · Treatments